ETFs Holding ARDX »    ARDX Historical Stock Prices »
ARDX News Video: Fri, Jan 6, 2017, 1:44 PM — Friday's ETF with Unusual Volume: VNQI

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Ardelyx is a biopharmaceutical company focused on developing medicines for the treatment of renal diseases. Co.'s product pipeline includes: Tenapanor, which is the primary product candidate in Co.'s renal portfolio for the treatment of hyperphosphatemia (high levels of blood phosphorus) in end-stage renal disease patients on dialysis; and RDX013, which is Co.'s small molecule program for the potential treatment of patients with elevated serum potassium. In addition to its development for hyperphosphatemia, Co. has completed development of tenapanor for the treatment of irritable bowel syndrome with constipation and is pursuing collaborations to bring it to market in this indication. Self directed investors in Ardelyx Inc will be interested in keeping up with all Ardelyx Inc news they can find, both ARDX news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on ARDX. At RediNews, we simplify this task by presenting both ARDX news releases originating from Ardelyx Inc itself, and ARDX news from a variety of media outlets. Visitors can browse this news online and through our ARDX RSS news feed.


ARDX News — Articles, Videos, & Press Releases

Analysts Expect VTHR Will Reach $147
Thursday, May 16, 2019, 8:19 AM — ETF Channel
Analysts Anticipate 13% Gains Ahead For VTWO
Monday, April 15, 2019, 8:20 AM — ETF Channel
How The Pieces Add Up: IWV Headed For $183
Friday, March 15, 2019, 7:27 AM — ETF Channel
Commit To Buy Ardelyx At $2.50, Earn 6.7% Annualized Using Options
Wednesday, March 13, 2019, 11:47 AM — Stock Options Channel
How The Pieces Add Up: PXSV Headed For $33
Thursday, February 7, 2019, 7:57 AM — ETF Channel
Implied SPSM Analyst Target Price: $36
Monday, January 7, 2019, 7:44 AM — ETF Channel
Sum Up The Parts: Russell 2000 Has 21% Upside
Friday, November 30, 2018, 7:30 AM — ETF Channel
SPSM's Underlying Holdings Imply 27% Gain Potential
Tuesday, October 30, 2018, 7:26 AM — ETF Channel
Commit To Buy Ardelyx At $2.50, Earn 8.3% Annualized Using Options
Wednesday, October 24, 2018, 12:09 PM — Stock Options Channel
Sum Up The Pieces: IBB Could Be Worth $146
Thursday, September 27, 2018, 8:02 AM — ETF Channel
Investors Snag ARDX Even Cheaper Than Its Secondary Stock Offering
Thursday, September 6, 2018, 4:17 PM — Dividend Channel
The Math Shows IBB Can Go To $144
Thursday, August 23, 2018, 8:00 AM — ETF Channel
How The Parts Add Up: IWV Headed For $183
Monday, July 23, 2018, 8:55 AM — ETF Channel
First Week of ARDX August 17th Options Trading
Thursday, June 21, 2018, 10:40 AM — Stock Options Channel
How The Parts Add Up: SPTM Headed For $38
Thursday, June 21, 2018, 8:12 AM — ETF Channel
Ardelyx Stock Sees Short Interest Fall 55.8%
Tuesday, June 12, 2018, 3:21 PM — Market News Video
ARDX is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:


RediNews invites those seeking web page financial content for any internet portal, especially any vertical portal specializing in the markets where there is a web page for business, web page for markets, web page finance, etc., to integrate our free web site content, our RSS news feeds. These RSS feeds are found throughout our website wherever news and custom stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic financial content is ideal for sites that already feature stock data content such as historical stock price information whether in the form of a historical stock price table or a web page chart image, to supplement the other custom stock market content displayed.

ARDX News | | Copyright © 2013 - 2019, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.